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Abstract
Background: Scabies is an ancient disease (documented as far back as 2500 years ago). It affects about 300 million
people annually worldwide, and the prevalence is as high as about 60 % in Indigenous and Torres Strait Islander
children in Australia. This is more than six times the rate seen in the rest of the developed world. Scabies is
frequently complicated by bacterial infection leading to the development of skin sores and other more serious
consequences such as septicaemia and chronic heart and kidney diseases. This causes a substantial social and
economic burden especially in resource poor communities around the world.
Discussion: Very few treatment options are currently available for the management of scabies infection. In this
manuscript we briefly discuss the clinical consequences of scabies and the problems found (studies conducted in
Australia) with the currently used topical and oral treatments. Current scabies treatment options are fairly ineffective
in preventing treatment relapse, inflammatory skin reactions and associated bacterial skin infections. None have
ovicidal, antibacterial, anti-inflammatory and/or anti-pruritic properties. Treatments which are currently available for
scabies can be problematic with adverse effects and perhaps of greater concern the risk of treatment failure. The
development of new chemical entities is doubtful in the near future. Though there may be potential for immunological
control, the development of a vaccine or other immunotherapy modalities may be decades away.
Summary: The emergence of resistance among scabies mites to classical scabicides and ineffectiveness of current
treatments (in reducing inflammatory skin reactions and secondary bacterial infections associated with scabies), raise
serious concerns regarding current therapy. Treatment adherence difficulties, and safety and efficacy uncertainties in
the young and elderly, all signal the need to identify new treatments for scabies.
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Background
Scabies has existed for at least 2500 years [1] and cur-
rently affects 300 million people annually worldwide. Its
listing as a neglected tropical disease by the World
Health Organization (WHO) in 2013 [2] recognised the
neglect in public and private sector expenditure on this
problem, the lack of attention at local, national, and
international levels, and the higher incidence of this in-
fection amongst the poor. In Australia it affects about 6
in 10 Aboriginal and Torres Strait Islander children at
any given time, more than six times the rate seen in the
rest of the developed world [3, 4]. The sequela of scabies
predisposes affected children to sepsis and other non-
suppurative invasive infections (e.g. lymphadenopathy,
acute post-streptococcal glomerulonephritis (APSGN)
and rheumatic fever) [5]. Outbreaks of APSGN usually
coincide with scabies outbreaks, which can contribute to
the development of chronic kidney disease and subse-
quent renal failure in adulthood [6]. It is usually reported
in Australian Aboriginal communities, other Oceanic na-
tions (Papua New Guinea, Fiji, Solomon Islands, Vanuatu)
[7], and in some parts of India, Chile and Trinidad [5],
and is uncommon outside these communities. APSGN
outbreaks do not always coincide with scabies outbreaks
elsewhere in the developed world. Scabies infestation has
a negative impact on the quality of life for infected individ-
uals (similar to that of psoriasis) resulting in substantial
stigmatisation and ostracism [8].
In this manuscript we focus on the challenges found
with diagnosis and treatment, emerging resistance among
scabies mites, and the need for further research in this
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field to identify new and alternative therapies for the treat-
ment and prophylaxis of scabies.
Discussion
Diagnosis
At present there is no accurate means of diagnosing sca-
bies in various clinical settings. Presumptive diagnosis is
often made on the basis of clinical signs, and a history of
contact with other scabies cases [9]. In practice (espe-
cially in resource poor settings), identifying scabies mite
from patient’s skin is challenging, and a negative result
by even experienced clinical staff, does not rule out sca-
bies. A positive response to therapy cannot exclude the
spontaneous disappearance of a skin condition other
than scabies, and a negative response to the first-line
treatment option does not exclude scabies, especially
with growing resistance among scabies mites [9]. Recent
findings in this field, e.g. serodiagnosis [10] shows prom-
ising potential; however, more research is required to
evaluate its efficiency in tropical clinical settings.
Treatments
There are several recommended treatment options for
scabies and these have been discussed in detail in a 2010
Cochrane review [11]. There are few obvious safe and ef-
fective scabicides currently (Table 1 and 2), and treat-
ment effectiveness can vary between clinical settings
[12]. So far, there is no international consensus on the
appropriate schedule for scabies treatment, and recom-
mendations in one nation may not be appropriate in
others [8]. The first line treatment options are topical
agents and require whole body application for many
hours duration [13]. Multiple treatment doses are often
recommended over days to weeks. Topical or oral anti-
biotic therapy may be required if secondary skin infec-
tion has developed [14]. It has also been advised that
close contacts of people with scabies should be treated
simultaneously, as they may be infected without yet
manifesting symptoms, and so can act as a reservoir of
infection [14, 15]. Treating the contacts may prevent re-
infection of the index cases following treatment [13]. The
logistics to treat all contacts simultaneously are significant
as it requires identification and treatment of all contacts
of an index case (e.g. family members, other coinhabitants,
medical and other supporting staff and others who may
come in contact with the index cases) [14, 16].
Most treatments (Table 2) are potentially hazardous
and are associated with moderate to severe side effects
(e.g. secondary eczematisation, oedema, erosions and/or
pyoderma) [17–22]. The most frequent complication of
topical scabicides is persisting post-scabies eczema (gen-
eralised eczematous dermatitis) resulting from irritant
effects of the various formulations [23]. These may es-
calate xerosis and worsen delayed-type eczema. Further,
it may be difficult to treat patients with secondary ecze-
matisation, erosions or ulcers using currently available
topical scabicidal agents such as permethrin, lindane, ben-
zoyl peroxide and sulphur, as they can cause serious cuta-
neous and systemic side-effects in addition to the problem
of compliance, resulting in poor treatment uptake [24].
Oral ivermectin is not widely available and has not
been approved for the management of scabies in many
countries [8]. At present, there is some observational
evidence of its effectiveness in controlling scabies out-
breaks in institutional settings including nursing homes
[5]. However; the safety or efficacy of ivermectin, the
sole oral therapy available, has not been well-established
in the elderly, patients with impaired liver function (po-
tential for toxicity resulting from long elimination half-
life [36 h]), children (aged <5 years) and pregnant
women, where the blood–brain barrier is incompletely
developed in the foetus, raising the potential for neurotox-
icity [12]. Because of the drug’s lipophilicity, ivermectin
may be poorly distributed in the asteototic stratum cor-
neum of the elderly compared to younger patients, leading
to mediocre therapeutic responses in the former patient
cohort and requiring combination therapy with topical
scabicides [12]. Ivermectin is not ovicidal, does not ad-
equately penetrate the thick egg shell of the scabies mite,
and is also ineffective against the younger stages of the
parasite (whose nervous system is poorly developed),
resulting in delayed therapeutic response [25].
Mass drug administration (MDA) programs have been
attempted to use ivermectin to control scabies in en-
demic communities around the world [26]. However,
such programs’ superiority over alternative topical treat-
ment is questionable [27, 28]. Ivermectin is indicated in
Australia only for crusted scabies or cases of typical sca-
bies when prior topical treatment has failed or has been
contraindicated [29]. It is generally recommended that for
maximum absorption ivermectin must be given in empty
stomach [30], which is a challenge in community-based
programs. Ivermectin administration can be labour-
intensive since the weight of all patients and the preg-
nancy status of all women of childbearing age must be
determined. Paradoxically, its use is not recommended
in those under 5 years of age when these are the most
vulnerable group (particularly among Aboriginal and
Torres Strait Islander children) [29, 30]. Institutional
outbreaks of scabies in aged care centres, prisons,
hospital wards and kindergartens are not uncommon
developed counties. In Australia it is neither given to
contacts of index cases, nor to households in heavily
infected large communities, as the prescribing informa-
tion does not support ivermectin administration to con-
tacts of index cases [31].
Permethrin resistance is widespread in other ectopara-
sites [32]. Evidence of increasing acaricide resistance
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leading to treatment failures has been reported (Table 1)
[33–37]. In vitro sensitivity data of scabies mites from
the last 10 years (Australian data) indicate that median
survival times to leading acaricides (ivermectin and per-
methrin) have increased 2–3 fold [33, 34]. Treatment
failure of permethrin as a scabicide in Indigenous commu-
nities in Australia (following MDA) and elsewhere has
been documented and it is the slowest-acting acaricide (in
vitro) in the Northern Territory, Australia [33, 38]. Per-
methrin resistance to scabies mites has been confirmed in
Table 1 Evidence of resistance to classical treatments used in scabies management
Study Indicative cure rate Drugs and treatment regimen Comments
Topical
Benzyl benzoate
[45] Moberg et al., 1984 (43 %; 6/14) benzyl benzoate (22.5 %) case report
[46] Yonkosky et al., 1990 (12 %; 23/195) benzyl benzoate (50 %) case study
[47] Nnoruka et al., 2001 (48 %; 14/29) benzyl benzoate (22.5 %) clinical exploratory study
[38] Glaziou et al., 1993 (48 %; 10/21) benzyl benzoate (10 %) RCT
Permethrin
[38] Leibowitz, 1993 (0 %; 0/11) permethrin 5 % cream un-controlled case study
[40] Fraser, 1994 permethrin (in vitro study)
[48] Walton et al., 2000 " (in vitro study)
[37] Pasay et al., 2006 " (in vitro study)
[39] Pasay et al., 2008 " (in vitro study)
[33] Mounsey et al., 2008 " (in vitro study)
[34] Mounsey et al., 2009 " (in vitro study)
[49] Saqib et al., 2012 quasi clinical study, re-infestation
after successful treatment (7 %; 4/60)
[50] Huffam et al., 1997 (0 %; 0/20) permethrin 5 % cream crusted scabies
Sulphur
[51] Coskey RJ, 1979 (0 %; 0/1) sulphur 5 % in an ointment case report
Oral
Ivermectin
[52] Glaziou et al., 1993 (70 %; 16/23) single dose, 100 μg/kg RCT, poor efficacy partly attributed
to the lower dose used in the study
[30] Currie et al., 1994 (0 %; 0/1) two doses, 200 μg/kg case report, crusted scabies
[33] Currie B.J 1999 five dose regimen, 200 μg/kg crusted scabies, monthly
administration failed to
prevent reinfestation
[36] Currie et al., 2004 (0 %; 0/2) seven doses, 270 μg/kg reinfestation following seven doses,
unpublished observations
[53] Brooks, et al., 2002 (56 %; 24/43) single dose, 200 μg/kg results evaluated at 3 weeks post
treatment
[33] Mounsey et al., 2008 In vitro study
[41] van den Hoek et al., 2008 (0 %; 0/7) case report
[34] Mounsey et al., 2009 In vitro study
[42] Ly et al., 2009 (30 %;16/53) single dose,
150–200 μg/kg
first RCT to report resistance of
ivermectin
[43] Rizvi et al., 2011 (78 %; 38/50) single dose, 200 μg/kg quasi clinical study
[54] Fujimoto et al., 2014 (0 %; 0/1) 6000 μg/week* 3 + 12000 μg/week *3 case report
[49] Saqib et al., 2012 quasi clinical study, re-infestation
after successful treatment (7 %; 4/60)
[50] Huffam et al., 1997 (60 %; 12/20) one-three doses, 200 μg/kg combined with
topical scabicide and keratolytic therapy
crusted scabies
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an animal model and its likely resistance mechanism has
also been documented [37, 39]. Since the first documented
case in Australia in 1994 [40], there have been reports of
resistance of Sarcoptes scabiei to ivermectin in vitro and
in vivo, including treatment failure in clinical trials [30, 34,
41–43]. MDAs programs that encounter poor compliance
increase the risk of developing resistance and targeted
treatment of index cases and contacts may be a better ap-
proach [44].
Conclusions
 Availability of a ‘fool-proof ’ diagnostic tool will
enable the selective treatment of affected individuals,
decrease the potential for escalating mite resistance,
and reduce the need for mass treatment and the
associated costs.
 Long-term adherence difficulties, safety and efficacy
uncertainties in the young and elderly, and growing
concerns over the development of resistance to
classical scabicides, all signal the need to identify
new treatment options for scabies (with greater
levels of treatment compliance in MDA programs)
to reduce the burden of infection in endemic
settings and the morbidity and mortality associated
with it.
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Table 2 An overview of classical treatments indicated for the management of scabies in Australia
Study Drugs Dosage Treatment
regimen
Contraindication Disadvantages Comments
Topical
[55, 56] Benzyl
benzoate
25 % solution one or several
consecutive 24-h
applications
pregnant women
and infants
burning or stinging,
pruritus, dermatitis,
convulsions (rare)
In use since 1930s; possible
neurological complications
with misuse; withdrawn in
the European Union due to
neurotoxicity concerns
[23, 56–58] Permethrin 5 % cream
(8–14 h) then
wash off
apply overnight infants aged
<2 months
mild burning, itching
stinging, pruritus, erythema,
tingling, persistent
excoriation, dystonia
(rare), convulsions (rare)
in use since the 1980s;
relatively expensive; growing
resistance among scabies
mites poor compliance
reported in mass community
intervention programs
[59, 60] Sulphur 2–10 %
precipitate
in petroleum
base
apply for 24 h,
and then wash
and reapply
repeat applications
for 3 days
noxious, malodorous messy;
not given as first-line agents;
multiple applications required;
can cause skin irritation;
has been used for centuries;
indicated in infants, pregnant
and lactating women;
inexpensive
Oral
[53, 61–63] Ivermectin 200 μg/kg
orally repeated
after 1–2
weeks
children aged
<5 years.; children
<15 kg; pregnant
or lactating women
transient side effects: g
astrointestinal disorders;
pustular rash, cellulitis;
abdominal pain, diarrhoea,
headache, vomiting,
hypotension, toxic
epidermal necrosis, mucosal
drug eruption, fever, anorexia,
lymph node swelling,
eosinophilia, pain of joint
and muscles, mazzotti
reaction
in use since 1980’s (for the mass
treatment of onchocerciasis,
and filariasis); not approved for
the treatment of typical scabies
(except in Japan, Brazil, France);
only indicated if symptoms
persists 3 weeks after application
of benzyl benzoate or permethrin;
no ovicidal activity, thus repeat
treatment is required; one report
of increased deaths among
elderly patients during scabies
outbreak in an institutional
setting (1997); there has been
considerable criticism on the
validity of this report, no other
studies have replicated these
findings
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